Acute urinary retention due to pseudoephedrine hydrochloride in a 3-year-old child.
(1/32)
Pseudoephedrine hydrochloride (PEH) is a sympathomimetic agent that is widely used in common cold disease in children. Though side effects of PEH are well known, it is preferred by many pediatricians in order to benefit from its symptomatic relief in common cold disease. A case of acute urinary retention due to PEH in a three-year-old boy is reported. The aim of this case report is to emphasize the clinical importance and differential diagnosis of PEH overdose in children and to discuss the appropriate treatment approach to PEH overdose in the emergency department. (+info)
Online concentration by head-column field-amplified with large-volume sample stacking using flow injection-capillary electrophoresis for the analysis of four active components in cold medicines.
(2/32)
A simple, effective, and sensitive online concentration method for the detection of dextromethorphan hydrobromide (Dex), chlorphenamine hydrogen maleate (Chl), pseudoephedrine hydrochloride (Pse) and paracetamol (Par) based on flow injection-capillary electrophoresis (FI-CE) analysis with head-column field-amplified sample stacking and large-volume sample stacking was developed. The background electrolyte (BGE) was a solution composed of 55 mM borate-15% (v/v) acetonitrile (ACN) (pH 9.3). The sample was injected electrokinetically between plugs of water. Under the optimum conditions, about a 30-fold improvement in the concentration sensitivity relative to normal CE methods was achieved, giving low limits of detection (LOD) of 1.94 x 10(-5), 0.64 x 10(-5), 1.16 x 10(-5) and 2.84 x 10(-5) mg/mL for Dex, Chl, Pse and Par, respectively. The repeatability (defined as RSD) was 1.01, 1.91, 0.89 and 0.92% with the peak-area evaluation and 1.94, 3.98, 2.66 and 3.27% with the peak-height evaluation for Dex, Chl, Pse and Par, respectively. This method has been successfully applied to the analysis of commercial pharmaceutical preparations containing Dex, Chl, Pse and Par. (+info)
Correction of severe hypotension by oral pseudoephedrine in a patient with idiopathic autonomic dysfunction.
(3/32)
The purpose of this case study was to review the use of an oral alpha-adrenergic agent to correct severe vasopressor-dependent hypotension in a patient with idiopathic autonomic dysfunction. Autonomic dysfunction resulting in severe hypotension that requires intravenous vasopressors can present challenges in the treatment of critically ill patients. Most patients are weaned from intravenous vasopressor agents once severe sepsis has resolved. Because of worsening idiopathic autonomic dysfunction during recovery from sepsis, this 76-year-old woman required prolonged care in the intensive care unit. Oral alpha-adrenergic agonist therapy in the form of pseudoephedrine proved to be a valuable treatment option to wean this patient off the vasopressor dependence and allow for placement in a long-term care facility. (+info)
Amphetamine and pseudoephedrine cross-tolerance measured by c-Fos protein expression in brains of chronically treated rats.
(4/32)
Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.
(5/32)
The Drug Enforcement Administration (DEA) is finalizing, without change, the Interim Rule with Request for Comment published in the Federal Register on July 25, 2007 (72 FR 40738). The Interim Rule removed the Controlled Substances Act (CSA) exemptions for chemical mixtures containing ephedrine and/or pseudoephedrine with concentration limits at or below five percent. Upon the effective date of the Interim Rule, all ephedrine and pseudoephedrine chemical mixtures, regardless of concentration and form, became subject to the regulatory provisions of the CSA. DEA regulated the importation, exportation, manufacture, and distribution of these chemical mixtures by requiring persons who handle these chemical mixtures to register with DEA, maintain certain records common to business practice, and file certain reports, regarding these chemical mixtures. No comments to the Interim Rule were received. This Final Rule finalizes the Interim Rule without change. (+info)
Acute coronary syndrome presenting after pseudoephedrine use and regression with beta-blocker therapy.
(6/32)
Pseudoephedrine, a common ingredient in cold relief drugs, dietary supplements and Chinese herbal tea, has potent sympathomimetic effects, impacting the cardiovascular system. The chemical properties and clinical effects of pseudoephedrine are similar to those of ephedrine, and its main effect is caused by the release of endogenous norepinephrine. A 45-year-old man who presented with chest pain following ingestion of pseudoephedrine--containing prescription medication is described. The patient was initially diagnosed with inferior myocardial infarction based on an electrocardiogram, and intravenous metoprolol was started pending coronary artery angiography. Metoprolol reversed the ST segment elevation and relieved the symptoms, and coronary angiography showed normal coronary arteries. The present case highlights beta-blocker therapy as part of an initial intervention of pseudoephedrine-related cardiac symptoms. (+info)
Pseudoephedrine use among US children, 1999-2006: results from the Slone survey.
(7/32)